China Asthma Therapeutics Market Size & Outlook, 2023-2030
China asthma therapeutics market, 2018-2030 (US$M)
Related Markets
China asthma therapeutics market highlights
- The China asthma therapeutics market generated a revenue of USD 959.4 million in 2023 and is expected to reach USD 1,661.2 million by 2030.
- The China market is expected to grow at a CAGR of 8.2% from 2024 to 2030.
- In terms of segment, anti- inflammatories was the largest revenue generating drug class in 2023.
- Combination therapy is the most lucrative drug class segment registering the fastest growth during the forecast period.
Asthma therapeutics market data book summary
| Market revenue in 2023 | USD 959.4 million |
| Market revenue in 2030 | USD 1,661.2 million |
| Growth rate | 8.2% (CAGR from 2023 to 2030) |
| Largest segment | Anti- inflammatories |
| Fastest growing segment | Combination therapy |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Anti- inflammatories, Bronchodilators, Combination therapy |
| Key market players worldwide | Teva Pharmaceutical Industries Ltd, GSK PLC, Merck & Co Inc, Roche Holding AG, AstraZeneca PLC, Boehringer Ingelheim, Sanofi SA, Koninklijke Philips NV, BD, Corvus Pharmaceuticals Inc |
Other key industry trends
- In terms of revenue, China accounted for 3.6% of the global asthma therapeutics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China asthma therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,661.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Asthma Therapeutics Market Scope
Asthma Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China asthma therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to asthma therapeutics market will help companies and investors design strategic landscapes.
Anti- inflammatories was the largest segment with a revenue share of 62.38% in 2023. Horizon Databook has segmented the China asthma therapeutics market based on anti- inflammatories, bronchodilators, combination therapy covering the revenue growth of each sub-segment from 2018 to 2030.
According to a study published by the UK’s NHS, the healthcare expenditure in China is projected to reach USD 25.2 billion by 2027, as the country has the largest population in the world. The growing geriatric population and increasing disease prevalence are inducing the increasing application of bronchodilators in the country.
The market is also being driven by the growing geriatric population, vulnerable to asthma and COPD. Moreover, city smog is responsible for aggravating asthma symptoms in children. Hence, with the growing prevalence of asthma, key companies are entering the market to gain a competitive edge.
The company is searching for manufacturing partners to help it access the market with a few respiratory treatments that it has either commercialized or is in the pipeline in other regulated areas. In addition, the biopharmaceutical sector is witnessing growth due to high investments in R&D by the Chinese government.
Reasons to subscribe to China asthma therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China asthma therapeutics market databook
-
Our clientele includes a mix of asthma therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China asthma therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into China asthma therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China asthma therapeutics market size, by drug class, 2018-2030 (US$M)
China Asthma Therapeutics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
